Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EQL Pharma AB ( (SE:EQL) ) has provided an update.
EQL Pharma AB’s extraordinary general meeting on 3 February 2026 approved the board’s proposal to introduce a long-term incentive programme for two key employees based on the issuance of up to 220,000 warrants. The warrants, to be priced at fair market value using the Black & Scholes model and exercisable in September 2030 at a subscription price set at 200% of the volume-weighted average share price after the April–December 2025 interim report, would result in a modest dilution of approximately 0.74% of share capital and votes if fully exercised, aligning key staff incentives with long-term shareholder value and the company’s continued expansion in niche generics.
More about EQL Pharma AB
EQL Pharma AB is a Lund-based pharmaceutical company specializing in the development and sale of niche generic prescription drugs, including hospital products, with a primary focus on the Nordic and broader European markets. The company has 47 niche generics currently launched and maintains a substantial pipeline of additional niche products planned for 2026 and beyond, working closely with contract manufacturers and major pharmaceutical partners in the EU and Asia. EQL Pharma is listed on Nasdaq Stockholm.
Average Trading Volume: 32,311
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.78B
For a thorough assessment of EQL stock, go to TipRanks’ Stock Analysis page.